ACURA PHARMACEUTICALS, INC (13)

Browse by Contract Category

Business Finance (11)
Intellectual Property (2)

Contracts

Acura Pharmaceuticals Inc. 2021 Restricted Stock Unit Award Plan (Filed With SEC on May 27, 2021)
Amended License, Development and Commercialization Agreement is made and entered into as of October 16, 2020 by the Registrant and between Abuse Deterrent Pharmaceuticals, LLC (Filed With SEC on March 31, 2021)
Common Stock Warrant issued June 28, 2019 to John Schutte (Filed With SEC on March 31, 2020)
License, Development and Commercialization Agreement is made and entered into as of June 28, 2019 by the Registrant and between Abuse Deterrent Pharmaceuticals, LLC (Filed With SEC on March 31, 2020)
Assignment of Promissory Note, Warrant and Security Agreement issued June 28, 2019 by John Schutte to Abuse Deterrent Pharmaceuticals, LLC (Filed With SEC on March 31, 2020)
Promissory Note Dated June 28, 2019 (Filed With SEC on February 28, 2020)
Promissory Note Dated May 1, 2019 (Filed With SEC on February 10, 2020)
Promissory Note Dated June 12, 2019 (Filed With SEC on February 10, 2020)
Promissory Note Dated March 25, 2019 (Filed With SEC on October 1, 2019)
Promissory Note dated October 5, 2018 issued to John Schutte (Filed With SEC on September 16, 2019)
Promissory Note dated November 21, 2018 issued to John Schutte (Filed With SEC on September 16, 2019)
Promissory Note dated December 20, 2018 issued to John Schutte (Filed With SEC on September 16, 2019)
Promissory Note dated January 28, 2019 issued to John Schutte (Filed With SEC on September 16, 2019)